Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System AtrophyMASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the efficacy ...

A new study indicates that the loss of brain volume associated with the Alzheimer's drug lecanemab shows the drug is working ...

Brain health is essential for maintaining focus, memory, and overall cognitive function. However, many people experience ...

Men at high risk of cardiovascular disease had brain volume changes a decade earlier than women, U.K. Biobank data showed.

Brain volume loss linked to new Alzheimer’s immunotherapies, such as lecanemab, is caused by the removal of amyloid plaques rather than neuronal damage.